Format

Send to

Choose Destination
Virol J. 2011 Jan 26;8:40. doi: 10.1186/1743-422X-8-40.

Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors.

Author information

1
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Abstract

Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (POL) or the late pp28 (UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds. POL-and pp28-luciferase displayed maximal expression 48 and 72 hours post infection, respectively. The pp28-luciferase virus achieved a wider dynamic range of luciferase expression (6-7 logs) and was selected for testing of inhibition by five anti-viral compounds. Luciferase expression highly correlated with plaque reduction and real-time PCR. The pp28-luciferase reporter system is rapid, reproducible, and highly sensitive. It may be applied to screening of novel anti-CMV compounds.

PMID:
21269468
PMCID:
PMC3041771
DOI:
10.1186/1743-422X-8-40
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center